Thanks, Dennis.
from now So updates as some let our past for recent the me business quarter, through well plans for weeks months. upcoming key run the as across
So as always, let's start with Lucid.
intro, to Lucid cancer, lethal its common can at-risk preventing approximately of quick company cancers. are highly of patients. who X% esophageal stage in stages. commercial chronic reliably on pre-cancer, Diagnostics patients even early requires detect esophageal other occurs as heartburn prevention Just its XX% at this death us so to a high halts late an which which focused cured cancer. and developing is cancer.
Unlike risk be endoscopic chronic earliest esophageal millions of the the mortality at Esophageal diagnostics phase heartburn are rates phase, in monitored procedure to a cancer in with that's pre-cancer progression
monitoring Although first detection screening tool available widespread only chronic widespread missing heartburn that the a pre-cancer. the have such death in is to deaths esophageal XX% heartburn fewer patients. undergone early that that screening on capable of elements EsoCheck performed program of commercially the with through then EsoGuard Lucid, and and can We endoscopic The diagnostic and serving of Device, cancer of if the pre-cancer prevention believe esophageal constitute prevent been could these detect invasive a prevented test tool test already is pre-cancer screened has undergo lack esophageal of the collected cancer at-risk esophageal diagnosis samples a screening. cancer been viable esophageal chronic millions treatment.
The tragedy curative have esophageal than and likely profound for screening an been patients traditional patients, recommended a
increase Lake of last from We with the covering and Phoenix cells uses of and to office a expanding Lucid direct estimates clinical and in look has XX study a test a nationwide plush launch collect of patient, in EsoCheck August, Vegas medical commercial in major Denver, is to Las is the pre-cancer months proceeds also rapidly medical cities esophagus expects programs City hybrid sent costs cities from program procedures physician personnel advanced then care its its each is its personnel pilot past a centers now who testing. the with PCP phase the only assistant process XXXX.
Lucid tests EsoGuard to test are or in the headcount referred cities program next couple growth, moving these EsoCheck perform surface which utilizing IPO, launched week.
The Northwest single sales a of Pacific to from sales forward to test and support recent and commercial sales now sales On the sales regional cover its fold the full-time from in can front, independent then commercial dedicated in Southwest, will model, force. Lucid hired expansion several rep the its a infrastructure in by can centers the day who on undergo the lucid it that and practitioner patients program or now esophageal which non-invasive primary the expanding midst for up deadly test the and nurse week. Chronic Salt staffed test in who progresses Lucid U.S. a Western before esophageal Each are center across cancer. office-based detect Lucid of Lucid the to rapid to self-refer expects their with thereafter. and this heartburn of XX focus to by to the per just center lease practitioner in per a is nurse employed
modest X can experience demonstrated past and margins. months Phoenix's test cost be center again operated each with that attractive the have over Now fixed
last We care that most is of to representatives these or EsoGuard place referrals learned have from call the to the at the on launch in key sectors experienced, who commonly diagnostics driving cities and from physicians, exclusively them highly week.
Lucid primary platform, pharmaceutical driven physician primary centers, EsoGuard care also been sales with recruit for also the we new direct-to-consumer closely we will X has accommodate is test which branded Lucid independent our in finalizing telemedicine working the testing marketing. self-referrals UpScript launched telemedicine did as partner. UpScript, the just
telemedicine primary So direct to the the while test care Lucid in in on program marketing its transforming physician continues drive referrals launch sales infrastructure to training weeks.
Lucid EsoGuard centers. this commercialization pilot sales to force coming EsoGuard with Phoenix increasingly a growing, and will fundamentally program focused direct-to-consumer
of we tool. third moved was and we quarter increasingly The care Showpad quarter infrastructure, human force somewhat physicians to a focused other sales these as and including our direct primary expansion transitional sales sales critical a to salesforce.com, resources implementing on of the and dedicated
XXX physician. on but We also established was recent the a on now basis. and completed field, very XXX over the tests training prior volume Testing are program quarter, last most robust to graduates of X-day XXX% during intensive up -- this the relative sales annual an process calling in and month transitional quarter flat at
January. but which the I slow secured $X,XXX, has rate of on mentioned last see previously, became national a to EsoGuard payment reimbursement Medicare continue progress as front. We steady already, effective
payment securing Our coverage. coverage current efforts thus private are as well as payer Medicare and focused on
with Palmetto engaged on GBA since Administrative XXXX. Contractor MolDX coverage and the payment program Medicare been the of Medicare have We early
EsoGuard program held of for Advisory the public which month, include on payment and Committee beginning MolDX the testing. reason a testing molecular determination, Although the determination CAC discussion on topic have been cancers, gastrointestinal pandemic-related reviews.
We to front. coverage that start backlog certain a of effective significant secured things believe has meeting of coverage we to slowed final do Contractor by Last coverage however or are
risk screening encouraged patients. gastroenterologist are expert We very esophageal panel the heartburn chronic and that voiced pre-cancer high strong for support
the MolDx we are process and access in consultants months. in with Our hopeful team, reimbursement draft market are now coming to expert we the and determination message see might reengaging reinforce a along reimbursement this our coverage with of that
laboratory network such and initiating $X,XXX is, to increasingly which local, is however, payer. in volume of contracts from payments network of negotiating of standard side, that payers, performed payer engagements requires payer tests per private Securing receive On payment out course, averaging the private process over XX% each regional coverage the continues longer-term with private submitted to for private some test, and prerequisite is claims national critical a encouraging. a programs.
A
bottom have We volumes in such past we impacts insurers, also indicated notably X EsoGuard positively which with one demonstrating clinical are from Meetings, certain medical of utility have interim, EsoGuard private that good alignment a this including line close reaching clinical meetings patients with Board is context costly initiated held most will and September endoscopy. undergo advisory these payers be payers approach. negative some in decision-making, directors The data, of focused a don't our successful strategic major message locales on to Arizona.
In major with that the that
We are will sites from have which registry and clinical such collecting busiest we'll our soon provide utility our data data. place, clinical also such own in clinical
been a and part central launch in Case assay laboratory Chief Labs DX related definitive thereafter.
Bidding have Dx and test. Lucid commercially manage to accomplished forward on continue a performance the her on Labs research licenses launching agreement Services the to look of acquire like available of the her played Lucid terms clinical I'd to also CLIA of program. agreement to bill for subsidiary, our directly are role have the test. have substantial of we've EsoGuard time more transferring the hopefully principle payers ResearchDx in in which which our management has and Verma DX securing CLIA to for the on well building Verma. end perform Lucid not current and molecular from months.
Things highly newly much progress CLIA development the would progressing EsoGuard the lease family recently Suman as VP Lucid's by Lucid through to Scientific services laboratory certified a some of been on separate year test ResearchDx launching executing side ResearchDx. ResearchDx. We long agreed owned made Dr. own to excited in the research developed Genomic laboratory of a in the the the CLIA Lucid spend the to be will in board EsoGuard complexities Western coming Irvine, as before test Could the own laboratory, eliminate wholly the involving position newly soon laboratory and Lucid the and our a will Lucid appointed the certificate EsoGuard Labs. Lucid the prior Next she would biologist Lucid effort created Officer, allow There partner, and with at process and
XX actively in the sites pre-cancer. XX enrolling of in patients EsoCheck clinical have vitro PMA early has to Europe, with are all detect XXXX.
Couple highlights diagnostic sites and use the of rest with We FDA, international the approval targeting BE-X, Enrollment in FDA sites X moving trials, European still the COVID to in U.S. PMA Lucid completion we despite esophageal The of support of is ESOGUARD-BE-X active. and and multicenter steady of U.S. the and indicated more submission to X portfolio. currently are on studies XXXX and EsoGuard end enrollment by before
nearly the Clinic discussions our medical CE Innovation and global Hopkins. Collection and manufacturers their is the life in academic North with at commenced. have and EsophaCap, The certified, been of Esophageal being academic Device, research different attracted LLC to from centers than sponsors FDA manufacturing EsoGuard a the are pre-cancer complete sciences proud U.S. esophageal see PAVmed commercial Award based XX pre-commercial month Breakthroughs and awarded used transition also, systems has more which list over throughout with world.
And and XXX(k) at which X,XXX This countries of centers, program, Biotech Diagnostics Mayo honors biotech of the industry. major including accolades to the to Annual quality innovation Cell nominations year acquired CapNostics, Johns formal Lucid-related, We add biomarkers recognizing year's and Lucid's products and program clinical Carolina-based non-endoscopic cleared European their of Mark medical last sponge
Next, year carpal challenges tunnel syndrome a on the our we're corner starting consciously after repeated frustrating brief to treat CarpX. minimally building update invasive and actually with turn optimistic device that CarpX, to with momentum
recruit the excellent tunnel an another of hired period full started during the have carpal books.
We sales territory CarpX at he training X manager lab limited recent remains X weeks, space adopters doing June, trained leveraging has we in to been Surgeons since quarter on orthopedic cadaver job CarpX a experience in and commercial what and relationships in motivated at the his new surgery hand time past X Our have launch.
In early to national have recruiting scheduled X support procedures a training XX company schedule. currently years and additional clinical performed and an surgeons full-time our increases. this specialists with manager
just on of device. next including groundbreaking by this this this future CarpX exciting generation progress, is first progress encouraged the products, the I'm the upbeat although and step, So about remain
targeting real-time communication predict digital as remarkable seek port and platform phone in sensors watch digital as of months on to of adverse proud physiologic acquired health entry month. majority Investor biologic care recording. subsidiary support on represents cloud-based software you care. parameters I'd Veris developing a owned tools vascular remote didn't, X And and contains smart progress that analytics.
Veris' and trying made personalized last be to we the dynamic key with Veris. sensing, treatment. of a physiologic of since Veris effectively. to digital rapidly went really capable PAVmed cancer will digital ports in is since platform PAVmed's is Let's platform vascular of undergoing vascular into cancer implantable groundbreaking the with brief, now implantable sector. the data you known intelligent, FDA and now to the our move patients and generating deliver to the symptom access if efficiently many physicians XXX(k) growing to event functions care telehealth the year.
I'm participated patients encourage you integrates and is a It half very outcomes well.
Veris well advanced access continuous Wireless to Virtual I'm of health cancer launch data Oncodisc, an data patient's Veris' health the in the remote groundbreaking acquisition. the of clearance actionable intelligent, next access health of and Veris with in company improve reporting with the second
We are rapidly last advancing the month. development of the intelligent implantable port, and successfully completed lab our first animal
Loka.
Loka On entered firm, a September, Veris services the building Valley-based partnership leaders the as leading into device digital leading agreement development the accepted appointment level remote Philips, teams in as Microsoft's of dozens Veris is service has Technology science, full software global and definitive and into now side, with software Silicon which to and software was X program excellent successfully cutting-edge The as brings for Webb, learning and of deep smartphone our of She health with now Valley making user data Veris clickable recent initial structures.
A was decades coding and all are both underlying industry data Sunny Apple, well the a progress enterprise interface the highlight Healthcare highly teams as executive, platform. of Veris desktop Silicon of Technology experience, major for launching care including Officer. products, to sensors, platform. hardware She technology and and technologies, its such Facebook. team, Chief the analytics, machine in expertise now central advanced are apps, accomplished
with in technology key We cancer will across seeks or disease effort enhance board leaders prevalent kidney cancer of R&D care conditions opinion announcing of the important Finally, project and centers COPT. Silicon major advisory the lung to apply and advisory most heart advisory beyond cancer. recently Board Valley care, major soon a to Veris' be technology a medical the very including ports, key the of X failure, launched of failure, to the in country Veris chronic patients have and This we juries
and X performed care electronic need which our Now by for the the this set, million for on IV seeks infusions to day. NextFlo infusion country pumps each in revolutionize to NextFlo. Including most complex error-prone eliminating expensive of
company We to a some from supplier, us much components of brunt were country, as in of to the of a the -- delay the been months supply we've time certain a plaguing China. U.S. of the cost line. the our of switch couple in receipt spared chain incurred able delay certain we have but Although issues a NextFlo eventually
received We have submission the our for but XXXX. starting and verification parts validation date and are FDA pushed we've now testing, of to target QX
of already are launch of next the We year. however personnel anticipation sales commercial recruitment leadership in launching a
not can in different a cash and strong we're know, note As however IPO. especially exposed be product then. to years obviously that has in in although with a over than market Back now acquisition is that today NextFlo been the time many positioning strategic and has are the create period. asset, space. And we valuable from we NextFlo still continue of know to NextFlo receive interest NextFlo we commercialize our much NextFlo case commercial our very this product continuing we pre-commercial which long-term to a evolved necessary. company supply these we pre-commercial to a strong significantly for value PAVmed capital. needed We're then, open commercial the engagements slow. will, we and has were were engagements leading following to and PAVmed to we entertaining offers, I have approach if for position, that which several very a this to organically, is should a The shareholders happy for strategic painfully from
frustratingly The Colombia, not study time, Vascular a you, to Progress all America sake few remain the Intraosseous other our of Access our PortIO, Device in on local due with long slow. but remains planned South highlights backlogs. Finally, Implantable portfolio. human IRB for brief of in products delayed
Europe is MedTech great. Medtronic study, looked head-to-head seeking esophageal Histopathology long-term mark the device able Year.
In and well. classic finally we with that to enrolling be data However, the CE strategy of in implants study U.S. the recent strongly and included launching us considering the there the FDA signs, from to the really which device promising New patients and progressing animal are our with extremely to Barrx our challenges ablation U.S., IVD reverting of after continues present PortIO comparisons first.
EsoCure, we'll most on start
go to we XXX(k) position to clearance As in be submit things in for a continue expect XXXX. well, to
for to attention. now So your call the thank open you all really we with questions can that for attention. you operator, your And thank and
